Obeagu Emmanuel Ifeanyi
Department of Biomedical and Laboratory Science, Africa University, Zimbabwe.
Ann Med Surg (Lond). 2025 Jul 18;87(9):5784-5791. doi: 10.1097/MS9.0000000000003620. eCollection 2025 Sep.
Anemia, characterized by a decline in hematocrit (Hct) levels, is a common and significant complication in cervical cancer. It often results from tumor-induced blood loss, chemotherapy, and inflammation. This review explores the clinical implications of anemia and Hct decline in cervical cancer, emphasizing their role in prognosis and treatment. We examine the pathophysiological mechanisms driving these changes, including tumor-associated blood loss and chemotherapy-induced bone marrow suppression. Additionally, the review highlights the impact of anemia on cancer progression, treatment resistance, and patient quality of life. Declining Hct levels in cervical cancer are associated with worse survival outcomes, reduced chemotherapy efficacy, and increased morbidity. Studies show that low Hct levels correlate with advanced disease stages and higher tumor burden, suggesting their potential as prognostic markers. Anemia in these patients can exacerbate symptoms such as fatigue and weakness, further affecting their overall well-being. The importance of early detection and treatment of anemia is emphasized, with therapies such as erythropoiesis-stimulating agents, iron supplementation, and blood transfusions being commonly employed to manage these changes.
贫血以血细胞比容（Hct）水平下降为特征，是宫颈癌常见且严重的并发症。它通常由肿瘤导致的失血、化疗和炎症引起。本综述探讨了贫血和Hct下降在宫颈癌中的临床意义，强调了它们在预后和治疗中的作用。我们研究了导致这些变化的病理生理机制，包括肿瘤相关失血和化疗引起的骨髓抑制。此外，该综述强调了贫血对癌症进展、治疗耐药性和患者生活质量的影响。宫颈癌中Hct水平下降与较差的生存结果、化疗疗效降低和发病率增加有关。研究表明，低Hct水平与疾病晚期和更高的肿瘤负荷相关，提示它们作为预后标志物的潜力。这些患者的贫血会加重疲劳和虚弱等症状，进一步影响他们的整体健康状况。强调了早期发现和治疗贫血的重要性，促红细胞生成素、补充铁剂和输血等疗法通常用于应对这些变化。
